rs4746 — GLO1 Glu111Ala

GLO1 Glu111Ala — When the Methylglyoxal Detox Slows Down

Your cells constantly generate methylglyoxal (MG)¹¹ methylglyoxal (MG)
A reactive dicarbonyl metabolite produced as a byproduct of glycolysis — every glucose molecule your body burns generates a small amount of MG, a byproduct of burning glucose. Left unchecked, MG damages proteins and DNA by forming advanced glycation end-products (AGEs)²² advanced glycation end-products (AGEs)
Irreversible protein modifications that accumulate with age and high glucose; associated with neurological dysfunction, vascular aging, and sleep disruption. The enzyme glyoxalase 1 (GLO1) is the primary gatekeeper that converts MG into a harmless byproduct before it can react with cellular proteins.

What makes GLO1 biologically fascinating beyond detoxification is that MG is not simply a toxin — it also functions as an endogenous GABA-A receptor agonist³³ endogenous GABA-A receptor agonist
GABA-A receptors are the brain's main inhibitory chloride channels; compounds that bind and activate them produce calming, sleep-facilitating, and anxiolytic effects similar to benzodiazepines. By controlling MG levels, GLO1 effectively regulates the tone of this inhibitory neurotransmitter system. The rs4746 Glu111Ala variant changes a glutamic acid to alanine at position 111 of GLO1, reducing the enzyme's catalytic efficiency and allowing MG to accumulate to slightly higher baseline levels.

The Mechanism

The rs4746 G allele encodes alanine at position 111 of GLO1. The reference T allele encodes glutamic acid. GLO1 is located on chromosome 6 and the gene is oriented on the minus strand, so the coding sequence change is c.332A>C (Glu→Ala). Functional studies in erythrocytes and brain tissue confirm that Ala111 homozygotes show approximately a 16% reduction in GLO1 enzymatic activity⁴⁴ 16% reduction in GLO1 enzymatic activity
Itokawa et al. 2011 measured red blood cell glyoxalase activity in patients stratified by genotype; Gabriele et al. 2014 confirmed the finding in leukocytes and post-mortem brain tissue from typically developing controls.

With reduced GLO1 activity, MG is cleared more slowly, leading to two downstream consequences. First, transiently elevated MG can provide greater GABA-A receptor stimulation, as demonstrated by Distler et al. 2012⁵⁵ Distler et al. 2012
Distler MG et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest, 2012 in their landmark study showing that GLO1 overexpression in mice depleted brain MG and increased anxiety, while pharmacological GLO1 inhibition restored MG and had anxiolytic effects. Second, chronically elevated MG drives AGE accumulation⁶⁶ AGE accumulation
Advanced glycation end-products form when MG reacts irreversibly with lysine and arginine residues in proteins; they are not cleared by GLO1 and accumulate over time unless scavenged by compounds like carnosine, which impairs neuronal protein function and disrupts sleep-regulating pathways.

The Evidence

The mechanistic foundation was established by Distler et al. 2012⁷⁷ Distler et al. 2012
Distler MG et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest, 2012, showing that physiological concentrations of MG selectively activated GABA-A receptors in primary neurons. This was extended by McMurray et al. 2016⁸⁸ McMurray et al. 2016
McMurray KMJ et al. Neuronal overexpression of Glo1 or amygdalar microinjection of methylglyoxal is sufficient to regulate anxiety-like behavior in mice. Behav Brain Res, 2016, who demonstrated anatomically that direct MG injection into the basolateral amygdala produced anxiolytic effects comparable to midazolam.

At the human population level, genome-wide association studies have directly implicated the GLO1 locus in insomnia. The largest insomnia GWAS to date — Watanabe et al. 2022⁹⁹ Watanabe et al. 2022
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet, 2022 — analyzed 593,724 cases and 1,771,286 controls and found genome-wide significant signals at the GLO1 locus (p = 1×10⁻¹¹), among 554 total risk loci. GLO1 locus variants were also among 202 loci identified in the earlier Jansen et al. 2019 Nature Genetics GWAS ¹⁰¹⁰ Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet, 2019.

The sleep-AGE connection was directly measured by Li et al. 2024¹¹¹¹ Li et al. 2024
Li et al. Associations of Advanced Glycation End Products with Sleep Disorders in Chinese Adults. Nutrients, 2024, who found that elevated plasma MG-H1 (an MG-derived AGE) was significantly associated with poor sleep quality, excessive daytime sleepiness, and insomnia in 1,732 adults. This confirms that the MG → AGE axis disrupts sleep independently of its GABA-A modulatory effects.

The functional consequence of carrying Ala111 was characterized in brain tissue by Gabriele et al. 2014¹²¹² Gabriele et al. 2014
Gabriele S et al. The GLO1 C332 (Ala111) allele confers autism vulnerability: family-based genetic association and functional correlates. J Psychiatr Res, 2014, who found significantly reduced glyoxalase activity in both leukocytes and post-mortem temporocortical tissue of Ala111 allele carriers, along with a strong negative correlation between glyoxalase activity and AGE levels (τ = −0.588, P < 0.01).

Practical Implications

For GT and GG carriers, the reduced GLO1 activity creates two actionable targets. First, dietary and supplementary strategies can scavenge MG before it forms AGEs. Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide that directly reacts with and neutralizes MG — Hipkiss 2017¹³¹³ Hipkiss 2017
Hipkiss AR. On the Relationship between Energy Metabolism, Proteostasis, Aging and Parkinson's Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine. Aging Dis, 2017 reviewed evidence that carnosine's carbonyl-scavenging activity can ameliorate MG-induced pathological processes. Second, reducing dietary sources of exogenous AGEs (processed foods high in advanced glycation products) lowers the overall glycation burden on the body's detoxification systems.

Interactions

GLO1 activity is supported by vitamin B6 (pyridoxal/pyridoxamine), which functions independently as a carbonyl scavenger and complements GLO1's enzymatic role in MG detoxification. Research in the context of carbonyl stress and psychiatric conditions has found that low pyridoxal levels amplify the consequences of reduced GLO1 activity, suggesting that B6 status is a modifier of the rs4746 phenotype. GLO1 copy number variation (found in ~2% of the population) produces 2-4 fold increases in enzyme activity that dwarf the effect of the Glu111Ala SNP; individuals with GLO1 copy number gains would be expected to have lower MG and lower AGE burden even if they also carry the G allele at rs4746.